BNP Paribas Financial Markets Has $1.80 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

BNP Paribas Financial Markets trimmed its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 59,710 shares of the biopharmaceutical company's stock after selling 58,275 shares during the quarter. BNP Paribas Financial Markets' holdings in TG Therapeutics were worth $1,797,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Quadrant Capital Group LLC increased its stake in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares in the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp increased its stake in TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new stake in TG Therapeutics during the 4th quarter worth approximately $75,000. 58.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TGTX. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Stock Up 1.0%

Shares of TGTX traded up $0.33 during mid-day trading on Friday, hitting $34.57. 1,042,767 shares of the company's stock were exchanged, compared to its average volume of 2,983,166. The company has a market cap of $5.49 billion, a PE ratio of -345.67 and a beta of 2.21. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48. The company has a 50-day simple moving average of $38.13 and a 200 day simple moving average of $34.22. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics's revenue was up 90.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.07) earnings per share. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.